A Review Article: Protein Engineering of Therapeutic Enzymes
DOI:
https://doi.org/10.31033/ijrasb.9.1.16Keywords:
enzymes, stimulus-responsive, FDA, personalizedAbstract
Through the development of advanced, stimulus-responsive pharmacological systems, protein engineering has the potential to alter the metabolic drug landscapes. Protein therapies are a fast growing category of FDA-approved medications that have the potential to improve clinical consequences in the long run. Protein therapeutics engineering is still in its preliminary phase; however recent advancements in protein engineering skills are being used to gain direct monitoring over pharmacodynamics. Drugs that are intended to be metabolized under specific conditions are known as stimulus-responsive protein medicines. Protein engineering is being utilized to develop biochemically based smart medicines that are tailored to the specific needs of each patient's condition. To meet the requirements of therapeutic applications, protein engineering adds new features and functionality to the process of bio-chemical and bio-physical modification of proteins. Given the immense potential of protein engineering approaches to adjust the activity of bio-catalysts, this review reviews the current studies that demonstrate both the advancements and the limitations of using these methods to therapeutic enzyme engineering in the pharmaceutical industry. The current review will concentrate mainly on three types of therapeutic based enzymes: Diagnostic enzymes, Fibrinolytic enzymes, and pharmaceutical enzymes, in which the protein is the restorative agent, prodrug-activating enzymes, provokes a therapeutic effect, and diagnostic enzymes, in which the remarkable specificity and selectivity of a protein offer advantages compared to conventional analytical techniques.
Downloads
References
Wohlgemuth, R., Modular and scalable biocatalytic tools for practical safety, health and environmental improvements in the production of speciality chemicals. Biocatalysis and Biotransformation, 2007. 25(2-4): p. 178-185.
Woodley, J.M., Protein engineering of enzymes for process applications. Current opinion in chemical biology, 2013. 17(2): p. 310-316.
Ali, M. and Q. Husain, Guar gum blended alginate/agarose hydrogel as a promising support for the entrapment of peroxidase: Stability and reusability studies for the treatment of textile effluent. International journal of biological macromolecules, 2018. 116: p. 463-471.
Chen, F. and R. Kumsta, M. Heinrichs (2011),«Oxytocin and Intergroup Relations: Goodwill is not a Fixed Pie». PNAS. 108(13): p. E45.
Dean, S.N., et al., Targeting and delivery of therapeutic enzymes. Therapeutic delivery, 2017. 8(7): p. 577-595.
Zhu, Y., et al., A dual functional nanoreactor for synergistic starvation and photodynamic therapy. ACS applied materials & interfaces, 2020. 12(16): p. 18309-18318.
Ali, M., H.M. Ishqi, and Q. Husain, Enzyme engineering: Reshaping the biocatalytic functions. Biotechnology and bioengineering, 2020. 117(6): p. 1877-1894.
Sheldon, R. and S. van Pelt, Evaluation of immobilized enzymes for industrial applications. Chem. Soc. Rev, 2013. 15: p. 6223-6235.
Dhanjal, J.K., et al., Computational Protein Engineering Approaches for Effective Design of New Molecules. 2019.
Bilal, M. and H.M. Iqbal, Tailoring multipurpose biocatalysts via protein engineering approaches: a review. Catalysis Letters, 2019. 149(8): p. 2204-2217.
Kurtzman, A.L., et al., Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins. Current Opinion in Biotechnology, 2001. 12(4): p. 361-370.
Vasserot, A.P., et al., Optimization of protein therapeutics by directed evolution. Drug discovery today, 2003. 8(3): p. 118-126.
Maheshwari, N., et al., Amino-terminal fusion of epidermal growth factor 4, 5, 6 domains of human thrombomodulin on streptokinase confers anti-reocclusion characteristics along with plasmin-mediated clot specificity. PLoS one, 2016. 11(3): p. e0150315.
Absar, S., et al., Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy. Journal of Thrombosis and Haemostasis, 2015. 13(9): p. 1545-1556.
Armstead, W.M., et al., tPA variant tPA‐A296–299 Prevents impairment of cerebral autoregulation and necrosis of hippocampal neurons after stroke by inhibiting upregulation of ET‐1. Journal of neuroscience research, 2018. 96(1): p. 128-137.
Weissenborn, R. and D.J. Nutt, Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation? Journal of psychopharmacology, 2012. 26(2): p. 213-220.
Armstead, W.M., et al., Tissue-Type Plasminogen Activator-A296–299 Prevents Impairment of Cerebral Autoregulation After Stroke Through Lipoprotein-Related Receptor–Dependent Increase in cAMP and p38. Stroke, 2016. 47(8): p. 2096-2102.
Goulay, R., et al., Optimized tPA: a non-neurotoxic fibrinolytic agent for the drainage of intracerebral hemorrhages. Journal of Cerebral Blood Flow & Metabolism, 2018. 38(7): p. 1180-1189.
Song, Q., et al., Dihydromyricetin attenuated Ang II induced cardiac fibroblasts proliferation related to inhibitory of oxidative stress. European Journal of Pharmacology, 2017. 807: p. 159-167.
Ledoux, L., Action of ribonuclease on two solid tumours in vivo. nature, 1955. 176(4470): p. 36-37.
Coombs, G.S., et al., Distinct Mechanisms Contribute to Stringent Substrate Specificity of Tissue-type Plasminogen Activator (∗). Journal of Biological Chemistry, 1996. 271(8): p. 4461-4467.
Ke, S.-H., et al., Identification of a hydrophobic exosite on tissue type plasminogen activator that modulates specificity for plasminogen. Journal of Biological Chemistry, 1997. 272(3): p. 1811-1816.
Rutkoski, T.J. and R.T. Raines, Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. Current pharmaceutical biotechnology, 2008. 9(3): p. 185-199.
Kobe, B. and J. Deisenhofer, Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A. Journal of molecular biology, 1996. 264(5): p. 1028-1043.
Tsurupa, G. and L. Medved, Identification and characterization of novel tPA-and plasminogen-binding sites within fibrin (ogen) αC-domains. Biochemistry, 2001. 40(3): p. 801-808.
Bakker, A.H., E.J.D. Weening-Verhoeff, and J.H. Verheijen, The Role of the Lysyl Binding Site of Tissue-type Plasminogen Activator in the Interaction with a Forming Fibrin Clot (∗). Journal of Biological Chemistry, 1995. 270(21): p. 12355-12360.
Cong, X., et al., Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations. Protein science, 2016. 25(8): p. 1451-1460.
Riccio, G., et al., A novel fully human antitumor ImmunoRNase resistant to the RNase inhibitor. Protein Engineering, Design & Selection, 2013. 26(3): p. 243-248.
Torrèns, I., et al., A mutant streptokinase lacking the C-terminal 42 amino acids is less immunogenic. Immunology letters, 2000. 70(3): p. 213-218.
Peplow, P.V., Glycosaminoglycan: a candidate to stimulate the repair of chronic wounds. Thrombosis and Haemostasis, 2005. 94(07): p. 4-16.
Wang, H., et al., Serine-578 is a major phosphorylation locus in human plasma plasminogen. Biochemistry, 1997. 36(26): p. 8100-8106.
Chen, Y., et al., Engineering subtilisin proteases that specifically degrade active RAS. Communications biology, 2021. 4(1): p. 1-13.
Mishra, M., et al., Repurposing the McoTI-II rigid molecular scaffold in to inhibitor of ‘Papain superfamily’cysteine proteases. Pharmaceuticals, 2021. 14(1): p. 7.
Choudhury, D. and S. Biswas, Structure-guided protein engineering of human cathepsin L for efficient collagenolytic activity. Protein Engineering, Design and Selection, 2021. 34.
Mushtaq, A., et al., Isolation and characterization of nprB, a novel protease from Streptomyces thermovulgaris. Pakistan Journal of Pharmaceutical Sciences, 2020. 33.
Gurewich, V., Therapeutic fibrinolysis: how efficacy and safety can be improved. Journal of the American College of Cardiology, 2016. 68(19): p. 2099-2106.
Gurewich, V., Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator. Journal of the American College of Cardiology, 1987. 10(5): p. 16B-21B.
Gladysz, R., et al., Discovery and SAR of novel and selective inhibitors of urokinase plasminogen activator (uPA) with an imidazo [1, 2-a] pyridine scaffold. Journal of medicinal chemistry, 2015. 58(23): p. 9238-9257.
Rabbani, S.A., et al., An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia, 2010. 12(10): p. 778-788.
Xu, X., et al., Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM). PloS one, 2014. 9(1): p. e85349.
Bifulco, K., et al., The soluble form of urokinase receptor promotes angiogenesis through its Ser88‐Arg‐Ser‐Arg‐Tyr92 chemotactic sequence. Journal of Thrombosis and Haemostasis, 2010. 8(12): p. 2789-2799.
Lu, Z., et al., Differentiation of adipose stem cells by nucleus pulposus cells: configuration effect. Biochemical and Biophysical Research Communications, 2007. 359(4): p. 991-996.
Carriero, M.V., et al., Regulation of cell migration and invasion by specific modules of uPA: mechanistic insights and specific inhibitors. Current drug targets, 2011. 12(12): p. 1761-1771.
Vickers, N.J., Animal communication: when i’m calling you, will you answer too? Current biology, 2017. 27(14): p. R713-R715.
Degen, S., B. Rajput, and E. Reich, The human tissue plasminogen activator gene. Journal of Biological Chemistry, 1986. 261(15): p. 6972-6985.
Stephens, R.W., et al., Heparin binding to the urokinase kringle domain. Biochemistry, 1992. 31(33): p. 7572-7579.
Franco, P., et al., Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility. The Journal of cell biology, 1997. 137(3): p. 779-791.
Novokhatny, V., et al., Tissue-type plasminogen activator (tPA) interacts with urokinase-type plasminogen activator (uPA) via tPA's lysine binding site: an explanation of the poor fibrin affinity of recombinant tPA/uPA chimeric molecules. Journal of Biological Chemistry, 1995. 270(15): p. 8680-8685.
Sun, Z., et al., Identification of a flexible loop region (297–313) of urokinase-type plasminogen activator, which helps determine its catalytic activity. Journal of Biological Chemistry, 1997. 272(38): p. 23818-23823.
Lu, W., et al., Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography. Molecular Pharmaceutics, 2021. 18(4): p. 1690-1698.
Hanaoka, S., S. Saijou, and Y. Matsumura, A novel and potent thrombolytic fusion protein consisting of anti-insoluble fibrin antibody and mutated urokinase. Thrombosis and Haemostasis, 2021.
Mican, J., et al., Structural biology and protein engineering of thrombolytics. Computational and structural biotechnology journal, 2019. 17: p. 917-938.
Niego, B.e., et al., t-PA–specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood, The Journal of the American Society of Hematology, 2012. 119(20): p. 4752-4761.
Nassar, T., et al., In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood, 2004. 103(3): p. 897-902.
Gettins, P.G. and K. Dolmer, The high affinity binding site on plasminogen activator inhibitor-1 (PAI-1) for the low density lipoprotein receptor-related protein (LRP1) is composed of four basic residues. Journal of Biological Chemistry, 2016. 291(2): p. 800-812.
Parcq, J., et al., Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell Death & Differentiation, 2012. 19(12): p. 1983-1991.
Broder, C., et al., Isolation of a prokaryotic plasmin receptor. Relationship to a plasminogen activator produced by the same micro-organism. Journal of Biological Chemistry, 1991. 266(8): p. 4922-4928.
Malke, H., B. Roe, and J.J. Ferretti, Nucleotide sequence of the streptokinase gene from Streptococcus equisimilis H46A. Gene, 1985. 34(2-3): p. 357-362.
Sazonova, I.Y., et al., Reprogrammed streptokinases develop fibrin‐targeting and dissolve blood clots with more potency than tissue plasminogen activator. Journal of thrombosis and haemostasis, 2009. 7(8): p. 1321-1328.
Baig, M.U. and J. Bodle, Thrombolytic therapy. StatPearls [Internet], 2020.
Altaf, F., S. Wu, and V. Kasim, Role of fibrinolytic enzymes in anti-thrombosis therapy. Frontiers in Molecular Biosciences, 2021. 8: p. 476.
Sheets, A.R., et al., Identification and characterization of novel matrix-derived bioactive peptides: a role for collagenase from Santyl® ointment in post-debridement wound healing? PloS one, 2016. 11(7): p. e0159598.
Alipour, H., et al., Therapeutic applications of collagenase (metalloproteases): A review. Asian Pacific Journal of Tropical Biomedicine, 2016. 6(11): p. 975-981.
Pham, C.H., et al., The role of collagenase ointment in acute burns: a systematic review and meta-analysis. Journal of wound care, 2019. 28(Sup2): p. S9-S15.
Hartig-Andreasen, C., L. Schroll, and J. Lange, Clostridium histolyticum as first-line treatment of Dupuytren’s disease. Danish medical journal, 2019. 66(2): p. A5527.
Hoy, S.M., Collagenase clostridium histolyticum: a review in Peyronie’s disease. Clinical drug investigation, 2020. 40(1): p. 83-92.
Iwakawa, N., et al., Transient Diffusive Interactions with a Protein Crowder Affect Aggregation Processes of Superoxide Dismutase 1 β-Barrel. The Journal of Physical Chemistry B, 2021. 125(10): p. 2521-2532.
Bracco, P., et al., CYP154C5 Regioselectivity in Steroid Hydroxylation Explored by Substrate Modifications and Protein Engineering. ChemBioChem, 2021. 22(6): p. 1099.
Rasetti-Escargueil, C. and M.R. Popoff, Antibodies and vaccines against botulinum toxins: available measures and novel approaches. Toxins, 2019. 11(9): p. 528.
Steward, L., M.F. Brin, and A. Brideau-Andersen, Novel native and engineered botulinum neurotoxins. Handb Exp Pharmacol, 2020. 263: p. 63-89.
Dong, M., G. Masuyer, and P. Stenmark, Botulinum and tetanus neurotoxins. Annual review of biochemistry, 2019. 88: p. 811-837.
Pirazzini, M., et al., Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacological reviews, 2017. 69(2): p. 200-235.
Fonfria, E., et al., The expanding therapeutic utility of botulinum neurotoxins. Toxins, 2018. 10(5): p. 208.
Kumar, R., et al. The botulinum toxin as a therapeutic agent: molecular structure and mechanism of action in motor and sensory systems. in Seminars in neurology. 2016. Thieme Medical Publishers.
Aurora, S.K., et al., OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56‐week PREEMPT clinical program. Headache: The Journal of Head and Face Pain, 2011. 51(9): p. 1358-1373.
Kim, H.-J., et al., Antinociceptive effects of transcytosed botulinum neurotoxin type A on trigeminal nociception in rats. The Korean Journal of Physiology & Pharmacology, 2015. 19(4): p. 349-355.
Burstein, R., et al., Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia, 2014. 34(11): p. 853-869.
Tao, L., et al., Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors. Nature communications, 2017. 8(1): p. 1-10.
Elliott, M., et al., Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems. PLoS One, 2017. 12(10): p. e0185628.
Zanetti, G., et al., Botulinum neurotoxin C mutants reveal different effects of syntaxin or SNAP-25 proteolysis on neuromuscular transmission. PLoS pathogens, 2017. 13(8): p. e1006567.
Elliott, M., et al., Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models. Science advances, 2019. 5(1): p. eaau7196.
Tang, M., J. Meng, and J. Wang, New engineered-botulinum toxins inhibit the release of pain-related mediators. International journal of molecular sciences, 2020. 21(1): p. 262.
Fonfria, E., S. Donald, and V.A. Cadd, Botulinum neurotoxin A and an engineered derivate targeted secretion inhibitor (TSI) A enter cells via different vesicular compartments. Journal of Receptors and Signal Transduction, 2016. 36(1): p. 79-88.
Rasetti-Escargueil, C. and M.R. Popoff, Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development. Toxins, 2021. 13(1): p. 1.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Journal for Research in Applied Sciences and Biotechnology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
editor@ijrasb.com 